Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 543

Results For "CE"

8971 News Found

HealthCRED secures US$ 1.2 million in seed funding
Startup | August 13, 2024

HealthCRED secures US$ 1.2 million in seed funding

The fresh funds will be used to enhance customer relationships, expand operations and develop state-of-the-art service


Morepen Labs Q1 FY25 profit surges 147% to Rs. 36.17 Cr
News | August 13, 2024

Morepen Labs Q1 FY25 profit surges 147% to Rs. 36.17 Cr

Morepen Labs successfully raised Rs. 200 Crore through QIP


Ashland completes second expansion of Viatel bioresorbable polymers manufacturing and R&D lab in Ireland
News | August 13, 2024

Ashland completes second expansion of Viatel bioresorbable polymers manufacturing and R&D lab in Ireland

This project is supported by the Irish Government through IDA Ireland


Novo Nordisk's H1 sales increased by 24% in Danish kroner
News | August 12, 2024

Novo Nordisk's H1 sales increased by 24% in Danish kroner

For the 2024 outlook, sales growth is now expected to be 22-28% at CER


Lupin Q1 FY25 profit up 77% at Rs. 801 Cr
News | August 12, 2024

Lupin Q1 FY25 profit up 77% at Rs. 801 Cr

Revenue up 16.3% to Rs 5,600 crore versus Rs 4,814 crore


Wockhardt Q1 FY25 revenue up 14%
News | August 12, 2024

Wockhardt Q1 FY25 revenue up 14%

EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year


Ami Organics reports Q1FY25 PAT lower 34% at Rs. 14.7 Cr
News | August 12, 2024

Ami Organics reports Q1FY25 PAT lower 34% at Rs. 14.7 Cr

Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore


Metropolis Healthcare posts Q1 FY25 at Rs. 38.1 Cr
News | August 12, 2024

Metropolis Healthcare posts Q1 FY25 at Rs. 38.1 Cr

Revenue from operations stood at Rs. 313.4 crore during Q1 FY25


Caplin Point listed on Forbes Asia’s “200 Best under a Billion” for 2024
News | August 11, 2024

Caplin Point listed on Forbes Asia’s “200 Best under a Billion” for 2024

The comprehensive criteria encompasses evaluation of debt management, sales growth, earnings-per-share performance, as well as returns on equity


HealthCare Global Enterprises posts Q1 FY25 PAT higher at Rs. 12.1 Cr
News | August 11, 2024

HealthCare Global Enterprises posts Q1 FY25 PAT higher at Rs. 12.1 Cr

Our centers are performing as expected or even better